Finally, we discuss a panel of potential biomarkers for response to anti-CTLA-4 therapy. CTLA-4 monoclonal antibody blockade has demonstrated the ability to provide durable clinical benefit. With increasing knowledge of how to effectively manipulate this and other T cell checkpoints, cancer ...
(2016). “Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.” Cell 167(2): 397-404 e399 in vivo CTLA-4 neutralization Bartkowiak, T., et al. (2015). “Unique potentia...
This section compares the effect of CTLA-4 blockade on cancer treatment by the antibody ipilimumab and the H11 nanobody. In cancer therapy, two factors play an essential role in generating an effective Anti-CTLA-4 antibody response; one is increasing the expression of CTLA-4 on tumor-associated...
Anti-CTLA-4 therapy requires an Fc domain for efficacy Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved "check-point"-blocking anticancer therapy... Blomberg,S Olga,Garforth,... 被引量: 0发表: 0年 Suppressing T cell motility ...
Harbour BioMed announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody in combination therapy with toripalimab for patients suffering from ...
Furthermore, mice bearing melanoma tumors with knockdown of IFN-γ receptor 1 (IFNGR1) have impaired tumor rejection upon anti-CTLA-4 therapy. These data highlight that loss of the IFN-γ signaling pathway is associated with primary resistance to anti-CTLA-4 therapy. Our findings demonstrate ...
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013;1:229-34... DN Tang,S Yu,J Sun,... - 《Cancer Immunol Res》 被引量...
anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy. ...
CTLA-4 blockade using anti-CTLA-4 monoclonal antibody therapy has great appeal because suppression of inhibitory signals results in the generation of an antitumor T-cell response. Both clinical and preclinical data indicate that CTLA-4 blockade results in direct activation of CD4+ and CD8+ effector...
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 2016;167:397-404... J Gao,L Shi,H Zhao,... - 《Cell》 被引量: 169发表: 20...